Prevada Medical is developing a disposable medical device designed to reduce the incidence of healthcare-associated respiratory infections in ICU patients by providing broad-spectrum lethality against pneumonia-related pathogens. This solution addresses the high costs and severe consequences associated with ventilator-associated pneumonia, which leads to significant morbidity, mortality, and financial burden on healthcare systems.
Funding
Funding not disclosed
Founders
Product
Problem
Healthcare-associated respiratory infections, particularly ventilator-associated pneumonia (VAP) in ICU patients, lead to significant morbidity, mortality, and financial burden on healthcare systems. Current prevention guidelines are often impractical in real-world clinical settings, resulting in high non-compliance rates. These infections contribute to increased antibiotic use, extended hospitalizations, and substantial non-reimbursed costs for hospitals.
Solution
Prevada Medical is developing a disposable medical device designed to reduce the incidence of healthcare-associated respiratory infections in ICU patients. The device provides broad-spectrum lethality against common pneumonia-related pathogens, including both gram-positive and gram-negative bacteria. This cost-effective solution aims to provide better protection against respiratory pathogens while reducing the workload burden on front-line staff. The device is easily replaced and disposed of every 12-24 hours, requiring minimal intervention from hospital staff and providing continuous protection.
Target Audience
The primary target audience includes hospitals and ICUs seeking to reduce the incidence of healthcare-associated respiratory infections, specifically ventilator-associated pneumonia, and improve patient outcomes.
Features
- Broad-spectrum lethality against common pneumonia-related pathogens.
- Disposable design for easy replacement and disposal.
- Seamless integration into existing ICU workflows with minimal staff intervention.
- Cost-effective solution to reduce the financial burden of VAP.